Scientists at Yale University adapted existing human cancer treatments to find a new version that could benefit both humans and dogs. After conducting multiple clinical trials involving over 300 dogs over the past eight years, the researchers say that their canine cancer vaccine has almost doubled the 12-month survival rate for dogs with some types of cancer.
Scientists at the University of Chicago have developed a new pacemaker that’s thinner than a human hair, wireless, and operated entirely by light from an optic fiber. The non-invasive device could help regulate heart activity or even stimulate neurons in a set pattern to treat symptoms of conditions like Parkinson’s.
Led by researchers from the University of Cambridge, a clinical trial examined the effectiveness of giving the immunotherapy drug infliximab earlier, as soon as possible after diagnosis. They employed what’s called a ‘top-down’ strategy, meaning the drug was given straight after diagnosis regardless of the patient’s symptom severity. They found that this early intervention significantly reduces complications of this often debilitating disease, including the need for surgery by a factor of 10.
Brain stem glioma, officially called diffuse intrinsic pontine glioma (DIPG), is rare and lethal, diagnosed in just 300 children annually in the United States. The two-year survival rate is 10%, and no drug is widely available for its treatment beyond radiotherapy. After the boy’s diagnosis, the family traveled to France to take part in a randomized controlled trial. He was randomly assigned the drug everolimus, which he took for more than 5 years with remarkable success.
Solar cell efficiency may get a bump from bumps. New research from Turkey’s Abdullah Gül University suggests that building tiny domes into the surface of organic solar cells could boost their efficiency by up to two-thirds, while capturing light from a wider angle.
A new hand-held portable device is not only extremely quick and easy to use but very cost effective, say scientists from the University of Florida and National Yang Ming Chiao Tung University in Taiwan. Compared to the costly alternatives of Mammograms, which expose women to radiation—or MRIs and ultrasounds which require expensive equipment—researchers called the device revolutionary.
Scientists at Queen Mary University of London have developed a drug to treat mesothelioma, a notoriously deadly and hard-to-treat cancer linked to asbestos, in the biggest breakthrough in two decades.
An international trial spanning five countries found that the new drug, ADI-PEG20, cuts off the tumor’s food supply and quadruples three-year survival rates. It is the first of its kind to be successfully combined with chemotherapy in 20 years.
A remarkable pilot project installed on a 787-ft. container ship has proven it’s possible to capture emissions from the smokestacks of cargo ships with 78% efficiency and convert the CO2 into limestone pebbles, which can be offloaded and sold. London startup Seabound, funded by a US$1.5-million grant from the UK Government, partnered up with global shipping company Lomar to install the carbon capture equipment on one of its older and dirtier-burning ships, a medium-sized vessel capable of carrying more than 3,200 shipping containers.
Ninety-four percent of transgender people said that they were either a little or a lot more satisfied with their lives since they transitioned, the 2022 U.S. Transgender Survey (USTS) by the National Center for Transgender Equality (NCTE) found. The study, which is the latest edition of the influential survey of transgender people, involved 92,329 transgender and nonbinary respondents answering questions about various aspects of their lives from October 19 to December 5, 2022.
Amsterdam University Medical Center (UMC) and Radboud UMC researchers have developed an algorithm that, based on patient MRI scans and other data, can determine within a week if a particular antidepressant will, offering faster relief and minimizing often painful and damaging side effects. “This is important news for patients,” said Liesbeth Reneman, Professor of Neuroradiology at Amsterdam UMC. “Normally, it takes six to eight weeks before it is known whether an antidepressant will work.”
